RS57406B1 - Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak - Google Patents

Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak

Info

Publication number
RS57406B1
RS57406B1 RS20180743A RSP20180743A RS57406B1 RS 57406 B1 RS57406 B1 RS 57406B1 RS 20180743 A RS20180743 A RS 20180743A RS P20180743 A RSP20180743 A RS P20180743A RS 57406 B1 RS57406 B1 RS 57406B1
Authority
RS
Serbia
Prior art keywords
group
compound
mmol
methyl
general formula
Prior art date
Application number
RS20180743A
Other languages
English (en)
Serbian (sr)
Inventor
Satoru Ikegami
Atsushi Watanabe
Kimio Hirano
Tadashi Ohyama
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Publication of RS57406B1 publication Critical patent/RS57406B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20180743A 2013-06-12 2014-06-12 Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak RS57406B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013123968 2013-06-12
EP14811154.5A EP3009426B1 (en) 2013-06-12 2014-06-12 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
PCT/JP2014/065643 WO2014200075A1 (ja) 2013-06-12 2014-06-12 4-アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬

Publications (1)

Publication Number Publication Date
RS57406B1 true RS57406B1 (sr) 2018-09-28

Family

ID=52022361

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180743A RS57406B1 (sr) 2013-06-12 2014-06-12 Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak

Country Status (28)

Country Link
US (2) US9593081B2 (enExample)
EP (1) EP3009426B1 (enExample)
JP (1) JP6276760B2 (enExample)
KR (1) KR102212981B1 (enExample)
CN (1) CN105431416B (enExample)
AU (1) AU2014279113B2 (enExample)
BR (1) BR112015030315B1 (enExample)
CA (1) CA2914997C (enExample)
DK (1) DK3009426T3 (enExample)
ES (1) ES2669977T3 (enExample)
HR (1) HRP20180703T1 (enExample)
HU (1) HUE039015T2 (enExample)
IL (1) IL242912A0 (enExample)
LT (1) LT3009426T (enExample)
MX (1) MX369804B (enExample)
MY (1) MY168609A (enExample)
NO (1) NO3009426T3 (enExample)
NZ (1) NZ715837A (enExample)
PH (1) PH12015502745B1 (enExample)
PL (1) PL3009426T3 (enExample)
PT (1) PT3009426T (enExample)
RS (1) RS57406B1 (enExample)
RU (1) RU2662806C2 (enExample)
SG (1) SG11201510121RA (enExample)
SI (1) SI3009426T1 (enExample)
TR (1) TR201807659T4 (enExample)
WO (1) WO2014200075A1 (enExample)
ZA (1) ZA201600135B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3009426T3 (enExample) * 2013-06-12 2018-09-29
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3541801A4 (en) * 2016-11-18 2020-04-29 Dow AgroSciences LLC 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
JP7159214B2 (ja) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Pge2レセプター調節剤としてのフェニル誘導体
BR112019024114A2 (pt) 2017-05-18 2020-06-02 Idorsia Pharmaceuticals Ltd Composto, e, métodos de modulação de uma resposta imune e de profilaxia ou tratamento de uma condição
JP7159215B2 (ja) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Pge2レセプター調節剤としてのピリミジン誘導体
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
US11479550B2 (en) 2017-05-22 2022-10-25 Ono Pharmaceutical Co., Ltd. EP4 antagonist
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
CN117643587A (zh) * 2018-02-05 2024-03-05 深圳市原力生命科学有限公司 用于治疗癌症的杂二环羧酸
CN108997252B (zh) * 2018-07-27 2020-04-28 常州大学 一种恶二唑衍生物的绿色合成方法
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1489588A (zh) * 2001-01-31 2004-04-14 �Ʒ� 用作pde4同功酶抑制剂的噻唑基,噁唑基,吡咯基,和咪唑基羧酸酰胺衍生物
RU2315746C2 (ru) * 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
US20040023853A1 (en) 2002-05-23 2004-02-05 Peri Krishna G. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
AP2006003534A0 (en) 2003-09-03 2006-04-30 Pfizer Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
DE602005015215D1 (de) 2004-05-04 2009-08-13 Raqualia Pharma Inc Orthosubstituierte aryl- oder heteroarylamidverbindungen
MXPA06011555A (es) 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
WO2006087355A1 (en) * 2005-02-16 2006-08-24 Solvay Pharmaceuticals B.V. 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators
CA2648729A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
CA2654811A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008017164A1 (en) 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
EP2114877B1 (en) * 2007-02-26 2012-12-26 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
BRPI0814403A2 (pt) * 2007-07-02 2015-01-27 Hoffmann La Roche Devirados de imidazol como antagonistas de receptor ccr2
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
CN102026961B (zh) 2008-05-14 2014-04-09 安斯泰来制药株式会社 酰胺化合物
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
CA2806121C (en) * 2010-09-21 2018-10-09 Eisai R&D Management Co., Ltd. Pharmaceutical composition
US8828987B2 (en) 2010-12-10 2014-09-09 Rottapharm Biotech S.R.L. Pyridine amide derivatives as EP4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
US9181279B2 (en) 2011-07-04 2015-11-10 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
NO3009426T3 (enExample) * 2013-06-12 2018-09-29

Also Published As

Publication number Publication date
RU2662806C2 (ru) 2018-07-31
BR112015030315A2 (pt) 2017-07-25
HUE039015T2 (hu) 2018-12-28
AU2014279113A1 (en) 2016-01-21
RU2015155585A (ru) 2017-07-17
MX2015017161A (es) 2016-04-06
PH12015502745A1 (en) 2016-03-14
EP3009426A4 (en) 2016-10-19
KR102212981B1 (ko) 2021-02-04
NZ715837A (en) 2020-01-31
CA2914997C (en) 2021-07-20
HRP20180703T1 (hr) 2018-06-15
CN105431416A (zh) 2016-03-23
WO2014200075A1 (ja) 2014-12-18
US20170128431A1 (en) 2017-05-11
LT3009426T (lt) 2018-07-25
TR201807659T4 (tr) 2018-06-21
DK3009426T3 (en) 2018-05-28
MY168609A (en) 2018-11-14
ZA201600135B (en) 2017-04-26
MX369804B (es) 2019-11-21
IL242912A0 (en) 2016-02-01
US9855257B2 (en) 2018-01-02
NO3009426T3 (enExample) 2018-09-29
JP6276760B2 (ja) 2018-02-07
AU2014279113B2 (en) 2018-04-12
SI3009426T1 (en) 2018-06-29
PH12015502745B1 (en) 2019-01-25
SG11201510121RA (en) 2016-01-28
BR112015030315B1 (pt) 2022-10-04
US9593081B2 (en) 2017-03-14
US20160130232A1 (en) 2016-05-12
PL3009426T3 (pl) 2018-09-28
PT3009426T (pt) 2018-06-08
KR20160018745A (ko) 2016-02-17
JPWO2014200075A1 (ja) 2017-02-23
ES2669977T3 (es) 2018-05-29
CN105431416B (zh) 2019-01-08
EP3009426B1 (en) 2018-05-02
CA2914997A1 (en) 2014-12-18
EP3009426A1 (en) 2016-04-20
HK1221215A1 (zh) 2017-05-26

Similar Documents

Publication Publication Date Title
RS57406B1 (sr) Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak
JP6918819B2 (ja) オルトミクソウイルス感染の処置に有用な三環式化合物
TW200843744A (en) Dual-acting antihypertensive agents
EP1845972A2 (en) Novel heteropyrrole analogs acting on cannabiniod receptors
RS57090B1 (sr) Derivat piridina
TW200524605A (en) Therapeutic agents
EP2520566A1 (en) New Pharmaceutical Compounds
CN108430974A (zh) RORγ调节剂
KR20100122512A (ko) 질소 함유 이환성 복소환 화합물
JP2024534111A (ja) 芳香環系を含有する生物アンタゴニスト、その製造方法及び応用
CN104662008B (zh) 四唑化合物的脱保护方法
TW201245187A (en) Pyrazole derivatives
JP2023552655A (ja) ボロン酸化合物
JP2008539181A (ja) Ep1受容体アンタゴニストとして有用なフラン化合物
HK1221215B (zh) 4-炔基咪唑衍生物和含有其作为有效成分的药物
AU2023268460A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
EA049406B1 (ru) Ингибиторы tead
JPWO2010113952A1 (ja) ムスカリン受容体拮抗薬